Hummm...not so fast my friend. DARPA and the U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) headquartered in Sigonella, Italy with Laboratory Detachments in Cairo, Egypt, Camp Lemonnier, Djibouti, and Accra, Ghana want this along with other offerings by the company. Part of the reason that COVI-STIX, which results are outstanding and does have a registration of results platform on Apple and Android phones, has not gotten FDA approval is due to the product NOT having a large manufacturing ability in the US which DARPA and the US Military demand. Once that is accomplished FDA will approve COVI-STIX. I believe FDA approval is on hold by request although we will never know. Do not forget that ANP is well connected with the US military and the US military is well connected to Japan and the military of a dozen countries. ANP will give SORRENTO the ability to test multiple disease and contaminants at the same time and SORRENTO will give them the money and added personnel to have greater exposure.
The Parties intend to structure the Transaction as a reverse triangular merger in which a newly-formed subsidiary of Sorrento will merge with and into ANP.
News 
Market Data 
Discover 
AI
